Summary: GLP-1 receptor agonists help PCOS by improving insulin sensitivity, reducing compensatory hyperinsulinaemia, promoting weight loss, and thereby lowering androgen levels and potentially restoring menstrual regularity
As of June 2025, the branded version of liraglutide, Saxenda, generated $165 million in annual sales alone, and the market for GLP-1s could be set to hit over $126 billion in sales by 2029
For patients taking GLP-1 receptor agonists such as semaglutide or dulaglutide, there is currently no evidence suggesting that allulose interferes with medication efficacy or causes adverse interactions
BPC-157 is not a painkiller that masks symptoms
Without targeted supplementation and regular blood work, you are essentially flying blind
I always feel like Im in great hands and look forward to my bi-weekly IVs